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During the process of optimizing the salt
form of LF-3-88 (tartrate, hydrochloride, or
trifluoroacetate), we found unexpectedly that
the tartrate salt of LF-3-88 gave less robust
results in the SmartCube test in comparison
to its trifluoroacetate or hydrochloride salts.
On the other hand, all three tested salt forms
gave similar results in the FST.
Abstract
Preclinical and clinical studies demonstrated that the inhibition of cholinergic
supersensitivity through nicotinic antagonists and partial agonists can be used
successfully to treat depressed patients, especially those who are poor respond-
ers to selective serotonin reuptake inhibitors (SSRIs). In our effort to develop
novel antidepressant drugs, LF-3-88 was identified as a potent nicotinic acetyl-
choline receptor (nAChR) partial agonist with subnanomolar to nanomolar
affinities for b2-containing nAChRs (a2b2, a3b2, a4b2, and a4b2*) and supe-
rior selectivity away from a3b4  (Ki > 104 nmol/L) and a7-nAChRs
(Ki > 10
4 nmol/L) as well as 51 other central nervous system (CNS)-related
neurotransmitter receptors and transporters. Functional activities at different
nAChR subtypes were characterized utilizing 86Rb+ ion efflux assays, two-elec-
trode voltage-clamp (TEVC) recording in oocytes, and whole-cell current
recording measurements. In mouse models, administration of LF-3-88 resulted
in antidepressive-like behavioral signatures 15 min post injection in the Smart-
Cube test (5 and 10 mg/kg, i.p.; about 45-min session), decreased immobility
in the forced swim test (1–3 mg/kg, i.p.; 1–10 mg/kg, p.o.; 30 min pretreat-
ment, 6-min trial), and decreased latency to approach food in the novelty-sup-
pressed feeding test after 29 days chronic administration once daily (5 mg/kg
but not 10 mg/kg, p.o.; 15-min trial). In addition, LF-3-88 exhibited a favorable
profile in pharmacokinetic/ADME-Tox (absorption, distribution, metabolism,
excretion, and toxicity) assays. This compound was also shown to cause no
mortality in wild-type Balb/CJ mice when tested at 300 mg/kg. These results
further support the potential of potent and selective nicotinic partial agonists
for use in the treatment of depression.
Abbreviations
ACh, acetylcholine; ADME-Tox, absorption, distribution, metabolism, excretion,
and toxicity; BBB, blood–brain barrier; CNS, central nervous system; CYP, cyto-
chrome P450; FST, forced swim test; hERG, human ether-a-go-go-related gene; HS,
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high sensitivity; LS, low sensitivity; nAChR(s), nicotinic acetylcholine receptor(s);
NIMH-PDSP, National Institute of Mental Health Psychoactive Drug Screening
Program; NSF, novelty-suppressed feeding; SEM, standard error of the mean; SNRI,
serotonin norepinephrine reuptake inhibitor; SRM, selected reaction monitoring;
SSRI, selective serotonin reuptake inhibitor; TEVC, two-electrode voltage-clamp;
TFA, trifluoroacetic acid.
Introduction
Depression is a common and frequently severe neurologi-
cal condition, affecting ~120 million people worldwide.
Numerous therapeutic agents exist for the treatment of
depression that target monoamine transporters selective
for the neurotransmitters serotonin and norepinephrine
(Berton and Nestler 2006). However, a considerable pro-
portion of patients respond poorly to these drugs (Ruhe
et al. 2006). The cholinergic hypothesis of depression
holds that hyperactivity of the cholinergic system over the
adrenergic system leads to depression (Janowsky et al.
1972). Preclinical and clinical studies have suggested the
hypothesis that reduction in cholinergic supersensitivity
with nicotinic antagonists and partial agonists has poten-
tial as a treatment for depression, especially for those
patients who are poor responders to selective serotonin
reuptake inhibitors (SSRIs) (George et al. 2008; Philip
et al. 2009).
Two major types of cholinergic receptors are musca-
rinic ACh receptors (mAChRs) and nicotinic acetylcho-
line receptors (nAChRs), both of which are widely
distributed in the central and peripheral nervous systems.
The G protein-coupled mAChRs are believed to be
involved in mood regulation and AChE-induced
depressive behavior. Neuronal nAChRs belong to the
ligand-gated ion channel superfamily of neurotransmitter
receptors. Heteromeric a4b2*-nAChRs, the predominant
form of nAChRs in the brain, are thought to have thera-
peutic benefits for a number of nervous system disorders
in preclinical or clinical studies such as nicotine depen-
dence, neuropathic pain, Alzheimer’s disease, and Parkinson’s
disease (Hurst et al. 2013).
The nicotinic ligand having received the most attention
as a potential antidepressant is mecamylamine. The first
controlled study to show evidence that mecamylamine
could ameliorate symptoms of mood disorders was a
monotherapy study treating Tourette’s disorder patients
(Shytle et al. 2002b). Mecamylamine appeared to be par-
ticularly efficacious in the treatment of symptoms of
major depression and showed significant improvements
for subgroups with attention deficit hyperactivity disorder
and hypomania, however, the subgroup sizes were very
small, and the comorbidity with Tourette’s disorder fur-
ther precludes any conclusions being drawn about the
efficacy of mecamylamine monotherapy in patients who
do not have Tourette’s disorder. Subsequent studies have
investigated mecamylamine’s efficacy as an augmentation
therapy in combination with SSRIs or serotonin norepi-
nephrine reuptake inhibitors (SNRIs) in treatment-resis-
tant patients. Most notable are the clinical trials utilizing
the positive enantiomer of mecamylamine, TC-5214.
Targacept achieved favorable results in a Phase IIb clinical
trial (Targacept press release, 2009), but collaborative
efforts with AstraZeneca resulted in multiple Phase III trials
that failed to meet their desired endpoints (AstraZeneca,
2012). While the Phase III failures do not disprove
TC-2514’s viability as a monotherapy, the compound
lacks nAChR subtype selectivity and is not particularly
potent. A recent estimate of the free mecamylamine con-
centration in brain indicates that it is likely on the edge
pharmacological relevance, blocking ~20% of a4b2*-
nAChR function (Weber et al. 2013). This could explain
inconsistencies between studies and illustrates the need
for more potent nAChR compounds that are highly
subtype-selective.
Targeting a4b2*-nAChRs (where the * indicates that
nAChR subunits other than those indicated are or may be
components of the receptor assembly) appears to be
required for antidepressant effects of nicotinic ligands
based on studies using nAChR subunit knockout animals
and pharmacological approaches (Picciotto et al. 1998;
Marubio et al. 2003; Caldarone et al. 2004; Rabenstein
et al. 2006; Rollema et al. 2007). While a6 subunits are
not widely distributed in the brain, they are, however,
prevalent in midbrain dopaminergic regions in the mam-
malian central nervous system (CNS), indicating their
potential association with depression (Klink et al. 2001;
Shytle et al. 2002a; Quik et al. 2011; Wu and Lukas
2011). In the past, translation of nAChR research into
viable pharmacotherapeutics has suffered in part due to
the insufficient selectivity of ligands away from ganglionic
a3b4*-nAChRs likely associated with unwanted side
effects like emesis and nausea (Gotti et al. 2009). Cytisine
derivatives have been shown to have relatively greater
selectivity than cytisine itself for b2*-containing nAChRs
over a3b4*nAChRs, and these agents have exhibited anti-
depressive-like behavior (Mineur et al. 2009). Sazetidine-
A and its analogs have been found to exhibit excellent
selectivity for b2-containing nAChRs over a3b4*- as well
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as a7-nAChRs. Replacing the acetylene bond with a
substituted isoxazole ring lead to the identification of
novel nicotinic ligands based on a pyridine ether scaffold
that are more bioavailable in vivo (Caldarone et al. 2011;
Yuan et al. 2013) while maintaining the key pharmaco-
phoric elements of sazetidine-A. Guided by the hypothesis
that selectivity for b2*-nAChRs by partial agonists is
essential for antidepressive-like behavior in vivo, we
report the characterization of a highly selective isoxazole-
containing b2* partial agonist, namely LF-3-88, in a bat-
tery of pharmacological and behavioral assays, along with
its preliminary pharmacokinetic/ADME-Tox (absorption,
distribution, metabolism, excretion, and toxicity) profile.
Materials and Methods
Synthesis
LF-3-88 is depicted in Figure 1 and was synthesized as
described previously (Liu et al. 2011). In brief, the desired
isoxazole was prepared via 1,3-dipolar cycloaddition of a
nitrile oxide, derived from the corresponding nitro
compound, to the appropriate alkyne. Subsequent depro-
tection of the precursor with trifluoroacetic acid (TFA)
and purification by High-performance liquid chromato-
graphy (HPLC) yielded the desired final compound as its
trifluoroacetate. Purity of the final compound (>98%)
was established by analytical HPLC, which was carried
out on an Agilent (Santa Clara, CA) 1100 HPLC system
with a Synergi 4 l Hydro-RP 80A column, with detection at
280 or 254 nm on a variable wavelength detector G1314A;
flow rate = 1.4 mL/min; 18-min gradient of 0–100%
methanol in water (both containing 0.05 vol% of TFA).
The number of equivalents of TFA in this nonstoichio-
metric compound was determined by elemental analysis.
All doses reported herein are expressed as the free base
equivalents.
Reagents and chemicals
Compound LF-3-88 was synthesized as described above,
and sertraline was purchased from Toronto Research
Chemicals (Ontario, Canada). Compounds were adminis-
tered by intraperitoneal (i.p.) injection in a volume of
Figure 1. Structures of selected a4b2*-nAChR agonists. Ki values are taken from literature:
aRollema et al. (2010), bMineur et al. (2009), cMineur
et al. (2011), dXiao et al. (2006).
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10 mL/kg. Solvents including acetonitrile, methanol, and
water were all Liquid chromatography–mass spectrometry
(LC-MS) grade and purchased from Fisher Scientific (Fair
Lawn, NJ). Formic acid was purchased from Sigma-
Aldrich (St. Louis, MO).
Radioligand-binding studies at CNS-related
neurotransmitter receptors and transporters
A broad-range screening study was carried out for com-
pound LF-3-88 at a 10 lmol/L concentration to further
determine its effects on 51 other CNS neurotransmitter
receptors and transporters, including serotonin receptors,
dopamine receptors, GABA receptors, biogenic amine
transporters, adrenergic receptors, muscarinic receptors,
opioid receptors, sigma receptors, and histamine recep-
tors. For experimental details, please refer to the Psycho-
active Drug Screening Program (PDSP) web site http://
pdsp.med.unc.edu/.
86Rb ion efflux assays
86Rb ion efflux assays were used as previously described
to characterize the functional effects of LF-3-88 (Lukas
et al. 2002). Cell lines naturally or heterologously express-
ing specific, functional, human nAChR subtypes were
used. The human clonal cell line TE671/RD naturally
expresses human muscle-type a1*-nAChRs, containing
a1, b1, c, and d subunits, with function detectable using
86Rb+ efflux assays. The human neuroblastoma cell line
SH-SY5Y naturally expresses autonomic a3b4*-nAChRs,
containing a3, b4, probably a5, and sometimes b2 subun-
its, and also displays function detectable using 86Rb+
efflux assays (Lukas et al. 1993). SH-SY5Y cells also
express homopentameric a7-nAChRs, however, their
function is not detected in the 86Rb+ efflux assay under
the conditions used. SH-EP1 human epithelial cells stably
transfected with human a4 and b2 subunits (SH-EP1-
ha4b2 cells) have been established and characterized with
both ion flux and radioligand-binding assays (Eaton et al.
2003). The recently established SH-EP1-h(a6/3)b2b3 cell
line also was used (Breining et al. 2012). These cells het-
erologously express human nAChR chimeric (a6/3)
subunits (wherein the extracellular, N-terminal, ligand-
binding domain of the human nAChR a6 subunit
replaces that domain in the nAChR a3 subunit) along
with human b2 and b3 subunits. These cells express func-
tional (a6/3)b2b3-nAChR that have pharmacological fea-
tures of receptors containing wild-type a6 subunits, such
as sensitivity to the a6b2b3-nAChR-selective functional
antagonist, a-conotoxin MII (Kuryatov et al. 2000; Mc-
Intosh et al. 2004). TE671/RD, SH-SY5Y, and transfected
SH-EP1 cell lines were maintained as low passage number
(1–26 from frozen stocks) cultures to ensure stable expres-
sion of native or heterologously expressed nAChRs as previ-
ously described (Lukas et al. 2002). Cells were passaged once
a week by splitting just-confluent cultures 1/300 (TE671/
RD), 1/10 (SH-SY5Y), or 1/40 (transfected SH-EP1) in
serum-supplemented medium to maintain log-phase growth.
Function of nAChR subtypes investigated was estab-
lished as previously described (Lukas et al. 2002; Liu et al.
2011; Yu et al. 2012). One newer modification on these
techniques involves low temperature incubation before
assays to increase the surface expression of high sensitivity
(HS) relative to low sensitivity (LS) a4b2 nAChRs and to
enhance surface expression of (a6/3)b2b3-nAChRs. The
~EC90 concentration of the full agonist carbamylcholine
was 100 lmol/L for SH-EP1-h(a6/3)b2b3 cells. Also,
because SH-EP1-ha4b2 cells express a variable mixture of
HS and LS ha4b2-nAChRs, and because sazetidine-A is a
full agonist at HS ha4b2-nAChRs while having zero or
nearly zero efficacy at LS ha4b2-nAChRs, as measured in
the 86Rb+ ion flux assay, we determined efficacies of com-
pounds studied at the two subtypes by comparing their
effects normalized to responses to sazetidine-A and
carbamylcholine, which is fully efficacious at both subtypes.
In brief, this allows us to determine efficacies of test com-
pounds at LS and HS a4b2 nAChRs, respectively, as the
ordinate values of the linear regressions at abscissa values
of 0% and 100% of sazetidine-A efficacy.
Whole-cell current recording assays
Standard whole-cell current recording combined with
instrumentation allowing rapid drug delivery and removal
was utilized as described previously (Liu et al. 2008). In
brief, SH-EP1-ha7 cells (Zhao et al. 2003) or SH-EP1-
ha4b2 cells (Wu et al. 2004) were placed onto 35-mm
culture dishes without poly(lysine) coating. Typically,
after allowing the cells to grow for 4–6 days, culture
dishes were placed on the stage of an inverted microscope
(Axiovert 200; Zeiss, Germany), and a standard external
solution (2 mL/min) was continuously superfused. Glass
microelectrodes made with 3–5 MΩ resistance between
pipette and extracellular solutions were used to obtain
>1 GΩ seals on the cell surface just prior to conversion
into standard whole-cell current recording mode by
applying suction to the pipette. After allowing exchange
between the pipette solution and the cytosol for 5‒
10 min, cells with attached pipettes were lifted gently
from the bottom of the culture dish via micromanipula-
tion of the pipette to improve kinetics of solution
exchange around the cell. Access resistance (Ra) was mea-
sured and accepted if it was less than 20 MΩ. Pipette and
whole-cell capacitance were both minimized, and series
resistance was compensated routinely to 80%. Cells were
2014 | Vol. 2 | Iss. 2 | e00026
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voltage-clamped at 60 mV, and inward currents
induced by indicated nicotinic agonists at the specified
concentrations were measured (200B amplifier; Molecular
Devices, Sunnyvale, CA). Current signals were typically
filtered at 5 kHz, acquired at 10 kHz, displayed and digi-
tized online (Digidata 1440A series A/D board; Molecular
Devices). Data acquisition and analyses were conducted
using pClamp9.2 (Molecular Devices), and results were
plotted by using Origin 5.0 (OriginLab Corp., North
Hampton, MA). All experiments were performed at room
temperature (22  1°C).
The external solution for SH-EP1 cell recording con-
tained 120 mmol/L NaCl, 5 mmol/L KCl, 2 mmol/L
MgCl2, 2 mmol/L CaCl2, 25 mmol/L D-glucose, and
10 mmol/L HEPES<< HEPES >>, pH 7.4 (Tris-base). For
conventional whole-cell recording, the pipette solution
contained 110 mmol/L Tris-phosphate dibasic, 28 mmol/
L Tris-base, 11 mmol/L EGTA<< EGTA >>, 2 mmol/L
MgCl2, 0.5 mmol/L CaCl2, and 4 mmol/L Na-ATP at pH
7.3. Drugs (standard compounds were obtained from
Sigma Chemical, St. Louis, MO) were delivered to the
recorded cell by a computer-controlled perfusion system
(SF-77B Perfusion Fast Step, Warner Instruments Incor-
porated, A Harvard Bioscience Company, Holliston, MA),
allowing the recorded cell can be completely surrounded
by the applied drug within 20 msec. The interval between
drug applications (2 min) was optimized specifically to
ensure stability of nAChR responsiveness (without func-
tional rundown).
Two-electrode voltage-clamp
Xenopus oocytes were injected with cRNAs encoding
human nicotinic receptor subunits (a4:b2 at 1:1 ratio or
a7). Three to five days after injection, oocytes were indi-
vidually placed in a custom made small volume chamber
and continuously perfused with oocyte Ringer’s solution
(OR2; 92.5 mmol/L NaCl, 2.5 mmol/L KCl, 1 mmol/L
CaCl2, 1 mmol/L MgCl2, and 5 mmol/L HEPES at pH
7.5). Drugs were delivered to the oocytes through a
ValveLink8.2 computer-controlled perfusion system
(Automate Scientific, Inc, Berkeley, CA). The chamber
was grounded through an agar KCl bridge. The oocytes
were voltage-clamped at 70 mV to measure agonist-
induced currents using a GeneClamp 500B amplifier
(Axon Instruments, Foster City, CA). The current signal
was filtered at 20 Hz with the built-in four pole low-pass
Bessel filter and digitized at 100 Hz.
Data analysis and statistics
To assess nAChR whole-cell current responses, both
peak and steady-state currents were measured during the
course of data acquisition and analyses. Results are
shown as mean  standard errors. Statistical analysis
was applied using paired t-tests when assessing data
obtained from a single cell, and Student’s t-test
(unpaired values) or one-way analysis of variance (ANOVA)
with Duncan’s multiple comparison were used to
compare data obtained from different cells. Values of P
less than 0.05 were considered significant. Curve fitting
for agonist and antagonist concentration–response data
were performed (Origin 5.0 software; OriginLab Corp.)
using the logistic equation to provide fits for maximal
and minimal responses, the EC50 or IC50 value, and Hill
coefficients.
Animals: SmartCube test
Male C57 BL6 mice (Taconic Farms) were used in the
SmartCube assay (PsychoGenics Inc., Tarrytown, NY).
Mice were received at 7 weeks old and group-housed in
OptiMICE ventilated cages with four mice/cage. Mice
were acclimated to the colony room for at least 1 week
prior to the first injections. All animals were tested in
SmartCube at 8‒10 weeks old.
Animals: forced swim test
Male Balb/CJ mice (Jackson Laboratories, Bar Harbor,
ME) were used in the forced swim test (FST). Upon
receipt, mice were assigned unique identification numbers
(tail marked) and were group-housed in OptiMICE venti-
lated cages. Mice were acclimated to the colony room for
at least 1 week prior to drug administration. Mice were
8–10 weeks of age at time of FST.
Animals: novelty-suppressed feeding test
Male C57 BL6/J (from Jackson Laboratories) mice were
used for these studies. Upon receipt at 6 weeks of age,
mice were single-housed in OptiMICE ventilated cages
and acclimated to the colony room for 1 week prior to
beginning of the dosing regimen at 7 weeks of age.
All mice were maintained on a 12/12 light/dark cycle
with the light on at 8:00 AM. The room temperature was
maintained between 20°C and 23°C with a relative
humidity between 30% and 70%. All animals were exam-
ined, handled, and weighed prior to initiation of the
study to assure adequate health and suitability and to
minimize nonspecific stress associated with manipulation.
Food and water are provided ad libitum for the duration
of the study. All animal experiments were conducted in
accordance with the National Institutes of Health (NIH)
Guide for the Care and Use of Laboratory Animals and
the PsychoGenics Animal Care and Use Committee.
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General procedures for behavioral studies
SmartCube test
To acquire initial in vivo evaluation of our nicotinic
ligands for behavioral effects relevant to psychiatric dis-
eases, we used SmartCube, an automated system in
which mouse behavior is captured by digital video using
novel, proprietary hardware that presents multiple chal-
lenges in a single test session and is analyzed with com-
puter algorithms. Digital videos of the subjects are
processed with computer vision algorithms to extract
more than 1400 dependent measures including frequency
and duration of behavioral states such as grooming, rear-
ing, etc., and many other features obtained during the test
session. Using machine learning techniques chosen to best
separate pharmacological effects of reference compounds,
the behavioral signatures of the mutant mice are then
assessed quantitatively.
Bioinformatics analysis
The most dominant of the features collected that define
the drug class signature are identified and ranked using
complex proprietary bioinformatics algorithms. The out-
come of a SmartCube run is a set of more than 1400
features (behavioral parameters) that can be used for vari-
ous analyses. Many of these features are correlated (e.g.,
rearing counts and supported rearing counts). Therefore,
we form statistically independent combinations of the ori-
ginal features (further referred to as decorrelated features)
that discriminate between the groups more effectively.
Next, we apply a proprietary feature ranking algorithm to
score each feature discrimination power to weight each
feature change by its relevance. The data obtained in this
way are used to define drug signatures for known refer-
ence compounds and to establish therapeutic class signa-
tures against which a test sample can be compared. The
neuropharmacological effects of a test compound can be
predicted by similarity to major classes of compounds,
such as antipsychotics, anxiolytics, and antidepressants
(Roberds et al. 2011).
Method
Mice are taken in their home cage to the SmartCube
suite of experimental rooms where they remain until they
are placed in the apparatus for a single testing session. A
standard SmartCube protocol runs for a single session
(~45 min). After the session mice are group-housed again
and brought back to the colony room. Any abnormal
behavior is noted. Mice were injected with cytisine (0.5
and 1.0 mg/kg), varenicline (1.0 and 3.0 mg/kg), or
LF-3-88 (5 and 10 mg/kg) 15 min before the test, during
which multiple experimental challenges were presented
over the course of the test session. At least 12 mice were
used in each treatment group.
Forced swim test
Procedures have been previously described (Porsolt et al.
1977). Na€ıve mice were individually placed into clear
glass cylinders (15 cm tall 9 10 cm wide, 1 L beakers)
containing 23  1°C water 12 cm deep (~800 mL).
Mice were administered vehicle, the SSRI sertraline
(10 or 20 mg/kg) as a positive control, or LF-3-88 (0.1,
0.3, 1, and 3 mg/kg, i.p.; or 1, 3, and 5 mg/kg, p.o.).
Thirty minutes following the administration, mice were
placed in the water, and the time the animal spent
immobile was recorded over a 6-min trial. Immobility
was defined as the postural position of floating in the
water. Only one session is required for the forced swim
test in mice.
Novelty suppressed feeding (NSF) test
Mice were tested in NSF on day 29 of treatment. Eighteen
hours prior to behavioral testing, all food was removed
from the home cage. The NSF test was carried out during
a 15-min period. The test chamber consists of a rectangu-
lar (14″ 9 20″ 9 6″) plastic box. The chamber floor is
covered with bedding (~0.5″). At the time of testing, ani-
mals were placed in the left front corner of the chamber
and two food pellets (regular chow) were placed on a
laminated white paper circle (13 cm in diameter) posi-
tioned in the center of the test chamber. The latency to
eat is defined by the animal holding the food with one or
both paws and taking a bite of the pellet and staying in
the center eating for at least 5 sec. The mice were video-
taped and tapes were scored by two trained observers
blind to the treatments. On test day (day 29), mice were
pretreated with water or LF-3-88 30 min prior to testing,
while imipramine was administered 60 min prior to test-
ing. Upon completion of NSF, about 50‒60 min after the
pretreatment, mice were decapitated and all animals from
all treatment groups except from the imipramine group
were processed for collection of trunk blood and whole-
brain tissue. Trunk blood was collected in microcentrifuge
tubes (1.5 mL) containing K2EDTA and kept on ice for
short-term storage. Within 15 min, the tubes were centri-
fuged immediately for 10 min at 10,000‒12,000 rpm in a
refrigerated centrifuge. Plasma was extracted and samples
stored in the 80°C freezer before testing. For brain tis-
sues, whole brains were deposited in microcentrifuge
tubes (1.5 mL) on dry ice. Samples are stored at 80°C
until analysis.
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Quantitative analysis
Concentrations of LF-3-88 in the brain and plasma were
determined using the previously developed UHPLC-MS-
MS method (Yuan et al. 2013). Compound LF-3-99
(10 ng/mL, See Fig. S1 for structure) was used as an
internal standard. Two selected reaction monitoring
(SRM) transitions (quantifier and qualifier) were moni-
tored for each compound with a dwell time of 50 msec/
ion as follows: LF-3-88: m/z 276 to 70 and m/z 276 to
207; and LF-3-99: m/z 304 to 98.
Statistical analysis
Data were analyzed by one-way ANOVA followed by post
hoc comparisons with Fisher’s test when appropriate.
Body weight data were analyzed using two-way repeated
measures ANOVA, followed by Fisher’s post hoc analysis.
An effect was considered significant if P < 0.05. Statistical
outliers that fell above or below 2 SD from the mean
were removed from the final analysis.
Results
Radioligand-binding activities at CNS-
related neurotransmitter receptors and
transporters
The in vitro binding affinities of the compounds (LF-3-88,
nicotine, and varenicline) are summarized in Table 1.
LF-3-88 was found to have potent interactions with b2-
containing nAChRs (a2b2, a3b2, a4b2, and a4b2*) with
Table 1. Binding affinities at seven rat nAChR subtypes.
Compound
Ki (nmol/L)
1
a2b2 a2b4 a3b2 a3b4 a4b2 a4b2*2 a4b4 a7 a7*2
LF-3-883 1.0  0.2 935 15.4  4.1 >104 0.6  0.1 3.0  0.4 1790 NA4 NA
Nicotine5 5.5 70.0 29.0 260 4.9 9.8 23.0 ND ND
Varenicline6 – – – 86 0.4 – 110 125 –
nAChR, nicotinic acetylcholine receptor; ND: not detected.
1See Materials and Methods.
2a4b2* or a7*, endogenous receptors prepared from rat forebrain. Besides a4, b2, or a7, other unidentified subunits may also be present. Details
are provided in the Materials and Methods.
3The Ki values for LF-3-88 are taken from a previous publication (Yu et al. 2012).
4NA: not active, defined as < 50% binding in the primary assay at 10 lmol/L.
5The Ki values for nicotine are taken from the PDSP Assay Protocol Book.
6The Ki values for varenicline are from the literature (Rollema et al. 2010).
Table 2. Potencies and efficacies of ligand agonism and inactivation of human a4b2-, a6/3b2b3-, and a3b4*-nAChRs1.
Compound LF-3-88 Nicotine Varenicline
Agonism
a4b2-nAChR
EC50 (nmol/L) 43 295 938
pEC50 7.37  0.19 6.53  0.05 6.03  0.15
HS Efficacy (%) 69  5.6 124  8.5 105  4.4
LS Efficacy (%) 7.8  3.8 70  5.9 34  2.8
Inactivation
a4b2-nAChR
IC50 (nmol/L) 32 427 32
pIC50 7.50  0.26 6.37  0.06 7.50  0.26
Efficacy (%) 68  4.9 92  2.1 79  3.3
Agonism
(a6/3)b2b3-nAChR
EC50 (nmol/L) 22.4 127 18
pEC50 7.65  0.06 6.9  0.03 7.75  0.07
Efficacy 10  0.27 56  0.06 17  0.5
Inactivation
(a6/3)b2b3-nAChR
IC50 (nmol/L) 192 85 68
pIC50 6.72  0.07 7.07  0.08 7.17  0.08
Efficacy (%) 74  2.8 26  1.4 74  2.6
Agonism
a3b4*-nAChR
EC50 (nmol/L) ND 30000 2200
Efficacy (%) ND 90 110
nAChR, nicotinic acetylcholine receptor.
1See Materials and Methods for details. The term “inactivation” is used because the compounds may be acting to desensitize receptors or as
competitive or noncompetitive antagonists, and further work is needed to make such a distinction.
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Ki values range of 0.6–15.4 nmol/L. It showed superior
selectivity for a4b2- (Ki = 0.6 nmol/L) over a3b4-
(Ki > 10
4 nmol/L) and a7-nAChRs (Ki > 10
4 nmol/L). In
the broad-range screening study, no inhibition caused by
10 lmol/L of compound LF-3-88 was greater than 50%
across 51 other CNS neurotransmitter receptors and
transporters, including serotonin receptors, dopamine
receptors, GABA receptors, biogenic amine transporters,
adrenergic receptors, muscarinic receptors, opioid recep-
tors, sigma receptors, and histamine receptors, indicating
that LF-3-88 has no significant activity at these targets.
(see Table S1).
In vitro functional characterization
Functionally, LF-3-88 was characterized using three tech-
niques: the 86Rb+ ion flux assay, two-electrode voltage-
clamp (TEVC) recording in oocytes, and whole-cell cur-
rent recording in SH-EP1-ha7 and SH-EP1-ha4b2 cells
(Table 2; Figs. 2 and 3). Consistent with the binding
assay results, LF-3-88 was selective for a4b2- and (a6/3)
b2b3-nAChRs with EC50 values of 43 and 22 nmol/L,
respectively, and IC50 values for inactivation of response
to full agonists of 32 and 192 nmol/L, respectively, in
the 86Rb+ ion flux assay (Table 2), while displaying no
significant agonist or antagonist activity at ganglionic
a3b4*- or muscle-type a1b1cd-nAChRs. TEVC record-
ings in oocytes confirmed LF-3-88 agonism at a4b2-
nAChRs with an EC50 of 79 nmol/L (Fig. 3A), and these
findings were confirmed in whole-cell current recording
from SH-EP1-ha4b2 cells (data not shown). At a7-nAC-
hRs, whole-cell recordings revealed that with a 2-min
pretreatment, LF-3-88 was only able to slightly inhibit
activation by 10 mmol/L choline, but it showed no ago-
nist activity and coapplication with choline had no effect
(Fig. 3B). No effect at a7-nAChRs was detected in oo-
cytes at concentrations as high as 20 lmol/L (Fig. 3C
and D). It is noteworthy that LF-3-88 exhibited potent
partial agonism at HS a4b2 receptors with an efficacy
that is 69% of that shown by carbamylcholine, but had
little or no intrinsic activity at LS a4b2 receptors. Inacti-
vation and/or desensitization of receptors by LF-3-88 to
carbamylcholine stimulation was equipotent at HS and
LS a4b2-nAChRs, as shown by the monophasic inhibi-
tion in Figure 2A. Nicotine and varenicline are provided
for reference in Table 2. Noticeably, varenicline shows
unusual properties for a high-affinity ligand with respect
to agonism as measured with the 86Rb+ ion flux assay.
This is due to the extended length of this endpoint assay
which was performed to measure the clinically relevant
IC50 for varenicline, which only reaches nanomolar con-
centrations in human brain at therapeutic doses (Weber
et al. 2013).
Preliminary in vitro ADME-Tox profile
The metabolic stability of LF-3-88 was studied using
human and mouse liver microsomes and cryopreserved
hepatocytes (See Table S2). Incubation with liver microsomes
for 1 h resulted in 81% (mouse) and 89% (human)
of LF-3-88 remaining unchanged, while exposure to
(a)
(b)
Figure 2. (A) Effects of LF-3-88 at nAChR subtypes. Specific 86Rb+
efflux (ordinate; percentage of control  SEM) was determined as
described in the Materials and Methods for intrinsic agonist activity
over a 9.5 min period for compound LF-3-88 at the indicated
concentrations (abscissa; log molar scale) on human a4b2-nAChR (●),
(a6/3)b2b3-nAChR (▼), a3b4*-nAChR (♦), or a1b1cd-nACHR (▲)
naturally or heterologously expressed by SH-EP1-ha4b2, SH-EP1-h(a6/
3)b2b3, SH-SY5Y, or TE671/RD cells, respectively. Also shown are
functional inactivation effects of pretreatment for 10 min with the
same agents at the indicated concentrations on subsequent agonist
action of an EC90 concentration of the full agonist, carbamylcholine
(applied in the continuing presence of the indicated agents), acting at
a4b2-nAChR (○), (a6/3)b2b3-nAChR (▽), a3b4*-nAChR (♢), or
a1b1cd-nAChR (△). Results are normalized to responses to a fully
efficacious concentration of carbamylcholine (see Materials and
Methods for details). Nanomolar agonist EC50 values and inactivation
IC50 values are provided in Table 2, as are agonism and inactivation
efficacies (normalized to those for a full agonist or antagonist,
respectively). (B) The unusual characteristic of sazetidine-A being a full
agonist at HS a4b2-nAChRs while having zero or nearly zero efficacy
at LS a4b2-nAChRs allows the determination of a ligand’s efficacies at
both HS- and LS-a4b2 in cells expressing a variable mix of the two
a4b2-nAChR isoforms. The ordinate intercepts of the linear
regressions at a sazetidine-A efficacy (abscissa) of 0% represent the
efficacies at LS a4b2-nAChRs, while the ordinate intercepts at a
sazetidine-A efficacy of 100% represent the efficacies at HS a4b2-
nAChRs. Values and standard errors are reported in Table 2.
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cryopreserved hepatocytes for 2 h resulted in 91%
(mouse) and 92% (human) of LF-3-88 remaining
unchanged. No significant inhibition was found toward
five different cytochrome P450 (CYP450) enzymes (2D6,
3A, 1A, 2C9, and 2C19) as shown in the Table S3. Fur-
thermore, LF-3-88 was found to be negative for muta-
genic potential against tester strains TA98, TA100, and
TA1535 with or without S9 cells present at four tested
Figure 3. (A) Representative two-electrode voltage-clamp recording responses to 1 mmol/L acetylcholine (ACh) or to LF-3-88 at the indicated
concentrations (for this and other panels, note time and current calibration bars), and dose–response relationship for LF-3-88 acting on human
a4b2-nAChRs expressed in Xenopus oocytes. LF-3-88 is a partial agonist at a4b2-nAChRs. (B) Representative, sequential, whole-cell current
recording responses of a7-nAChRs stably and heterologously expressed in the same SH-EP1-ha7 cells to (left-to-right) 1 lmol/L LF-3-88; 10 mmol/
L choline; 10 mmol/L choline during and after a 2 min pre-exposure to 1 lmol/L LF-3-88; 10 mmol/L choline during coexposure to 1 lmol/L LF-3-
88; 10 mmol/L choline after the aforementioned drug exposures; 1 mmol/L nicotine after the aforementioned drug exposures, with 2 min
intervals between drug applications. LF-3-88 has no agonist activity and only weakly at 1 lmol/L inhibits functional a7-nAChRs. (C) Typical two-
electrode voltage-clamp recording responses to 1 mmol/L acetylcholine (ACh) or to 20 lmol/L LF-3-88 at the indicated concentrations of a7-
nAChRs expressed in oocytes confirming lack of agonist activity. (D) Sample traces from two-electrode voltage-clamp recording of a7-nAChR
responses to 100 lmol/L ACh alone or in the presence of the indicated concentrations of LF-3-88 confirming weak if any antagonist activity of
LF-3-88 on a7-nAChR expressed in Xenopus oocytes.
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concentrations (5, 10, 50, or 100 lmol/L) (See Table S4)
in the Ames assays.
Acute behavioral pharmacology
The behavioral signatures in the SmartCube assay of
cytisine (0.5 and 1.0 mg/kg), varenicline (1.0 and 3.0 mg/
kg), and LF-3-88 (5 and 10 mg/kg) after 15 min of
preinjection (i.p.) are shown in Figure 4. All three of
these nicotinic partial agonists were found to exhibit
robust-mixed signatures at both of the tested doses. The
large “green” component of the bar graphs were observed
at 1.0 mg/kg for cytisine, and 5.0 and 10.0 mg/kg of LF-
3-88, suggesting potential antidepressive-like behavior.
Varenicline was found to show a side effect component
with about 30% probability at 3.0 mg/kg as indicated by
the maroon-colored component. Minimal side effects
were found at 1.0 mg/kg of varenicline and all the tested
doses of cytisine (0.5 and 1.0 mg/kg) and LF-3-88 (5 and
10 mg/kg).
For forced swim tests, mice were administered com-
pound LF-3-88 (0.1, 0.3, 1, and 3 mg/kg, i.p.) or the SSRI
antidepressant, sertraline, as a positive control (10 mg/
kg). Fisher’s post hoc tests showed that compound LF-3-
88 dose-dependently reduced immobility at 1 and 3 mg/
kg compared with a water-treated control group, but not
at 0.1 or 0.3 mg/kg, suggestive of a minimum effective
dose of 1 mg/kg (Fig. 5A). Moreover, LF-3-88 was also
found to reduce the immobility dose-dependently at an
orally administered dose of 1, 3, and 10 mg/kg (Fig. 5B).
Chronic novelty-suppressed feeding
Food-deprived mice experience a conflict between eating
food placed in the center of an arena and being in an
open, novel, bright space. This conflict results in a latency
to eat that is reduced by chronic treatment with antide-
pressant compounds. This latency reduction is quantified
and used in the experimental paradigm known as NSF.
Chronic administration of the tricyclic antidepressant
imipramine significantly decreased latency to eat
compared with control group (Fig. 6A). LF-3-88 treat-
ment at 5 mg/kg, but not at 10 mg/kg, significantly
decreased latency to eat compared with results using
water-treated control animals. No significant treatment
effect on body weight was found for the 4-week adminis-
tration of test compounds (repeated measures ANOVA;
Fig. 6B). No obvious behavioral changes were observed in
the NSF paradigm after 28 days oral administration of
both 5 and 10 mg/kg doses, suggesting these doses were
well-tolerated.
Mice were decapitated upon the completion of NSF,
and trunk blood and whole-brain tissue were collected
from all animals in the LF-3-88 treatment groups. Five
blood samples and whole-brain tissues were chosen ran-
domly for assessment. Plasma and brain levels of LF-3-88
were found to be 430  172 ng/mL and 14  4 ng/g at
the treatment dose of 5 mg/kg and 942  400 ng/mL and
31  11 ng/g at the treatment dose of 10 mg/kg.
Discussion
The cholinergic hypothesis of depression suggests that this
debilitating mental disorder results from hyperactivity of
the brain cholinergic system over the adrenergic system
(Janowsky et al. 1972), suggesting pursuit of nAChR
ligands as novel antidepressants. Recent Phase III findings
that the nonselective nAChR antagonist TC-5214 (Targa-
cept) failed to show efficacy as an adjunct therapy for
patients that were nonresponders to traditional antide-
pressant treatment may indicate that nicotinic ligands are
not good candidates for augmentation of SSRIs and
SNRIs or that patients resistant to these therapies will also
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be resistant to drugs targeting nAChR, however, it seems
most likely that TC-2514’s principal inadequacy is insuffi-
cient potency (Weber et al. 2013). Coupled with poor
selectivity, it would be unsurprising if a large enough
dose to reach the desired pharmacological endpoint at
b2*-nAChR in brain also caused undesirable side effects
that would at best result in a narrow therapeutic window
that is difficult to manage. It may also be that simple
nAChR antagonism is not an optimal strategy to treat
depressive symptoms in patients resistant to SSRIs and
SNRIs. A number of potent and selective a4b2-nAChR
partial agonists with distinct functional profiles have
been reported to exhibit antidepressive-like behavior
in vivo. In the present study, we characterized a selective
a4b2- and a6*-nAChR partial agonist LF-3-88 with a
favorable ADME-tox profile, and we evaluated its acute
and chronic effects in a variety of behavioral paradigms.
LF-3-88 is a potent a4b2-nAChR partial agonist with a
Ki value similar to that of varenicline (0.6 nml/L vs.
0.4 nmol/L). However, LF-3-88 showed little or no
binding affinity at a3b4- or a7-nAChRs (Ki > 10
4 vs. 86
and 125 nmol/L of varenicline) or at 51 other CNS-
related neurotransmitter receptors and transporters. Nota-
bly, LF-3-88 has relatively high efficacy at HS a4b2-nAC-
hRs (69% relative to that of carbamylcholine), but little
or no effect at LS receptors. This functional profile of LF-
3-88 differs from that of other known a4b2-nAChR par-
tial agonists such as cytisine and 3-(2-pyridinyl)cytisine
that show low intrinsic efficacy of no more than 10% at
both LS and HS receptors relative to that of ACh (Mineur
et al. 2009).
Compound LF-3-88 showed a favorable profile in
assays for CYP450 inhibition, metabolic stability, hERG
(human ether-a-go-go-related gene) inhibition, and Ames
toxicity. No significant inhibition was found against a
panel of five different CYP450 enzymes (2D6, 3A, 1A,
2C9, and 2C19) suggesting a decreased risk for drug–drug
interactions. Our previous pharmacokinetic study on
LF-3-88 showed that the compound was absorbed rapidly
and crossed the blood–brain barrier (BBB) in vivo (Yuan
et al. 2013). Taken together, these preliminary ADME-
Tox data encouraged us to conduct further studies in
vivo.
In the SmartCube test, cytisine, varenicline, and LF-3-
88 exhibited robust CNS drug-like signatures. In particu-
lar, antidepressive-like behavior were most pronounced
for LF-3-88 (5 and 10 mg/kg) and cytisine (1.0 mg/kg).
In addition, the side effect signature of LF-3-88 was less
than 10% at both tested doses, consistent with the good
tolerability of these doses in the NSF. This contrasts with
varenicline’s profile, which showed a steep change from
weak antidepressant effects at 1 mg/kg to significant side
effects (about 30%) at 3.0 mg/kg. As it has been reported
that cytisine is not tolerated by mice at a dose of
>1.5 mg/kg (Mineur et al. 2009), we tested lower doses
(0.5 and 1.0 mg/kg), and we observed no obvious side
effects. The antidepressant activity of LF-3-88 was further
confirmed using the classical mouse forced swim test, in
which LF-3-88 was found to decrease the time spent
immobile in a dose-dependent fashion with an estimated
minimal effective dose of 1 mg/kg. We carried out a pre-
liminary acute maximum tolerated dose study from which
we found that LF-3-88 temporarily decreased temperature
and active behaviors above 100 mg/kg but caused no seri-
ous toxic side effects or mortality up to 300 mg/kg in the
C57/BL6J mice, in contrast with varenicline which is
lethal at such doses when administered orally to Balb/C
mice (data not shown). These preliminary mouse acute
behavioral toxicity results indicate a reasonable therapeu-
tic window.
In the NSF study, chronic administration of either the
tricyclic antidepressant imipramine or LF-3-88 decreased
latency to eat compared with the water-treated group.
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However, this effect of LF-3-88 was only observed at the
lower dose (5 mg/kg) and was relatively weak. A similar
phenomenon was previously observed in the case of
3-(2-pyridinyl)cytisine, where only administration of the
lower dose of the compound (0.3 vs. 0.6 mg/kg) was
found to be effective in the NSF test (Mineur et al.
2009). Many nicotinic ligands have been reported to
decrease food intake and body weight, and as such may
affect the tendency of mice to initiate feeding. In our
study, we did not find a significant treatment effect on
body weight for the 4-week administration of LF-3-88. A
follow-up quantitative analysis of LF-3-88 in mouse
plasma and brain tissue showed that LF-3-88 was in the
brain and plasma and the exposure levels were dose
dependent. One possible explanation could be that nico-
tinic ligands that bind to a4b2-nAChRs might have
bimodal effects on anxiety. Nicotine has been found to
be anxiolytic at lower doses while being anxiogenic at
higher doses (File et al. 1998; Ouagazzal et al. 1999;
Cheeta et al. 2001). Moreover, anxiolytic and anxiogenic
effects of nicotine were observed at the same dose at dif-
ferent time points in the social interaction test (Irvine
et al. 1999). In general the literature findings on the
effects of nicotinic agonists in the chronic NSF paradigm
have been inconclusive. In this test, nicotine failed to
show significant behavioral changes after 28 days oral
administration in both BALB/cJ and C57BL/6J mice
(Vieyra-Reyes et al. 2008). After 14 days, repeat treatment
in C57BL/6J mice, cytisine and 3-(2-pyridinyl)cytisine
decreased the latency to eat; CP-601927 increased the
latency to eat while varenicline did not show any effect
(Mineur et al. 2009, 2011). Turner et al. (2010) found
that chronic treatment with sazetidine-A decreased the
time needed to approach food while no effect was
observed in the case of varenicline with male 129SvJ;
C57BL/6J F1 hybrid mice in the NIH (novelty-induced
hypophagia) paradigm. Furthermore, differences in doses,
routes of administration, pretreatment time, as well as
pharmacokinetics properties of individual compounds
may contribute to these contrasting data.
In conclusion, we have identified a selective a4b2- and
a6*-nAChR partial agonist, LF-3-88, with distinct func-
tional properties and a favorable ADME-tox profile. We
have evaluated its antidepressive-like behavior in Smart-
Cube, FST, and NSF mouse models. Although the antide-
pressant potential of LF is based on limited data, these
data suggest that the brain-penetrable compound LF-3-88
is well-tolerated in both acute and chronic studies that it
may be beneficial in balancing the agonism and antago-
nism of nAChRs that may be useful in clinical applica-
tions. These favorable properties of LF-3-88 were
achieved while eliminating the acetylene moiety of the
parent compound, Sazetidine-A, which is undesireable
due to the theoretically possible conversion into a highly
reactive oxirene.
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